According to DOJ, the company provided consulting services at below market value to certain health care providers that referred patients to NeoGenomics for lab testing.

The tests are intended for infectious and chronic disease detection and diagnosis as well as to aid in routine health monitoring.

NEW YORK – The Centers for Medicare & Medicaid Services issued a request for information Thursday seeking public input on potential updates to the Clinical Laboratory Improvement Amendments of 1988 ...

Of the roughly 1 million disputes taken through the law's arbitration process in Q2 2025, around 129,000 were for lab codes, with payments for basic tests averaging hundreds of dollars.

NEW YORK – A report released Wednesday by the US Department of Health and Human Services Office of Inspector General found that Medicare Part B spending on clinical lab testing continued to rise in ...

NEW YORK – Medicare administrative contractor Wisconsin Physicians Service Insurance Corporation (WPS) last week released a proposed local coverage determination that would cover non-next-generation ...

The Alzheimer's Drug Discovery Foundation (ADDF) said on Monday that it has partnered with the Michael J. Fox Foundation (MJFF) to develop minimally invasive biomarkers for Parkinson's and Alzheimer's ...

Abbott said on Thursday that its second quarter Diagnostics sales grew 42 percent to $3.09 billion compared to $2.17 billion in the year-ago quarter, helped along by its acquisition of Exact Sciences ...

Roche announced on Tuesday that it its Cobas hepatitis D test has been CE marked and the company is launching it in countries that accept the designation. The high-throughput test is intended for the ...

Under the policy, blood-based tests may be eligible for coverage if they either are cleared or approved by the US FDA or measure phosphorylated-tau 217.

The tests are intended for infectious and chronic disease detection and diagnosis as well as to aid in routine health monitoring. The QiaStat-Dx BCID GN Plus AMR panel is designed to detect 13 ...

The updated test showed 80 percent sensitivity for detecting colorectal cancer overall and 18 percent sensitivity for advanced precancerous lesions.